{
    "hands_on_practices": [
        {
            "introduction": "A core task in psycho-oncology is the systematic identification of patients experiencing emotional distress. While screening tools are invaluable, their raw scores can be misleading without proper interpretation. This exercise focuses on calculating the Positive Predictive Value ($PPV$), a crucial metric that reveals the real-world accuracy of a screening test and helps inform the design of efficient, multi-stage assessment pathways. ",
            "id": "4747811",
            "problem": "An oncology clinic uses the National Comprehensive Cancer Network Distress Thermometer with a cutoff of $4$ to screen for clinically significant distress in adults receiving active treatment. For this cutoff in a representative outpatient population, a validation study against a structured diagnostic interview reports sensitivity $0.80$, specificity $0.70$, and the point prevalence of clinically significant distress is $0.30$. Compute the positive predictive value of a positive screen at this cutoff as a single probability. Express your final answer as a decimal rounded to four significant figures. Then, based on the computed value, provide a concise interpretation of the clinical implications for triage and confirmatory assessment in psycho-oncology.",
            "solution": "The problem is well-posed and scientifically grounded, providing all necessary information to calculate the positive predictive value ($PPV$) of a screening test and interpret its clinical utility.\n\nLet $D$ be the event that a patient has clinically significant distress, and let $S^+$ be the event that the patient screens positive on the Distress Thermometer. The given information can be formally stated as:\n- The point prevalence of distress, $P(D) = 0.30$.\n- The sensitivity of the screen, $Sen = P(S^+|D) = 0.80$. This is the probability of a positive screen given that the patient has distress (a true positive).\n- The specificity of the screen, $Spc = P(S^-|D^c) = 0.70$, where $D^c$ is the event that the patient does not have distress and $S^-$ is the event of a negative screen. This is the probability of a negative screen given that the patient does not have distress (a true negative).\n\nFrom the prevalence, we can determine the probability that a patient does not have distress:\n$$ P(D^c) = 1 - P(D) = 1 - 0.30 = 0.70 $$\n\nFrom the specificity, we can determine the probability of a positive screen given that the patient does not have distress. This is the false positive rate.\n$$ P(S^+|D^c) = 1 - P(S^-|D^c) = 1 - Spc = 1 - 0.70 = 0.30 $$\n\nThe positive predictive value ($PPV$) is the probability that a patient has distress given that they have a positive screen, denoted as $P(D|S^+)$. We can compute this using Bayes' theorem:\n$$ PPV = P(D|S^+) = \\frac{P(S^+|D) P(D)}{P(S^+)} $$\n\nThe denominator, $P(S^+)$, is the total probability of a positive screen. It can be calculated using the law of total probability, which sums the probability of true positives and false positives:\n$$ P(S^+) = P(S^+|D) P(D) + P(S^+|D^c) P(D^c) $$\n\nNow, we substitute the given values into these formulas.\nFirst, we calculate the joint probability of a true positive, which is the numerator of Bayes' theorem:\n$$ P(S^+ \\cap D) = P(S^+|D) P(D) = (0.80)(0.30) = 0.24 $$\n\nNext, we calculate the joint probability of a false positive:\n$$ P(S^+ \\cap D^c) = P(S^+|D^c) P(D^c) = (0.30)(0.70) = 0.21 $$\n\nThe total probability of a positive screen is the sum of these two probabilities:\n$$ P(S^+) = 0.24 + 0.21 = 0.45 $$\n\nFinally, we can compute the $PPV$:\n$$ PPV = \\frac{P(S^+ \\cap D)}{P(S^+)} = \\frac{0.24}{0.45} $$\n\nPerforming the division:\n$$ PPV = \\frac{24}{45} = \\frac{8}{15} \\approx 0.533333... $$\n\nThe problem requires the answer to be rounded to four significant figures.\n$$ PPV \\approx 0.5333 $$\n\nBased on this computed value, the clinical implications are as follows:\nA positive predictive value of $0.5333$ means that for a patient who screens positive with the Distress Thermometer at a cutoff of $4$, there is a $53.33\\%$ probability that they truly have clinically significant distress. Conversely, this implies a false positive rate among those testing positive of $1 - 0.5333 = 0.4667$, or $46.67\\%$.\n\nThe clinical implications for triage and confirmatory assessment are significant. While the screen successfully enriches the population for distress (from a baseline prevalence of $30\\%$ to a post-test probability of $53.33\\%$), it is not sufficiently accurate to serve as a standalone diagnostic tool. The high proportion of false positives (nearly half of all positive screens) means that referring all positively screened patients directly to intensive psycho-oncology services would be highly inefficient, placing an unnecessary burden on limited clinical resources and potentially causing undue alarm for patients who are not, in fact, experiencing clinically significant distress. Therefore, a positive screen should function as a trigger for a mandatory second-stage, brief confirmatory assessment conducted by a trained staff member (e.g., a nurse, social worker, or psychologist) to validate the presence of distress before referral to more specialized psychiatric or psychological care. This two-tiered (screen-then-assess) model is essential for the efficient and effective allocation of psycho-oncology resources.",
            "answer": "$$ \\boxed{0.5333} $$"
        },
        {
            "introduction": "Once a clinical need is identified, the next step is to evaluate the effectiveness of potential interventions. This practice introduces the Number Needed to Treat ($NNT$), a powerful tool in evidence-based medicine for translating the results of a clinical trial into a single, intuitive number. Calculating the $NNT$ allows clinicians to quantify and communicate the practical impact of a treatment, such as a medication for managing a common chemotherapy side effect. ",
            "id": "4747807",
            "problem": "A randomized controlled trial in psycho-oncology evaluated gabapentin versus placebo for painful Chemotherapy-Induced Peripheral Neuropathy (CIPN) in adult patients receiving taxane- or platinum-based chemotherapy. The primary outcome was a clinically meaningful pain response at $8$ weeks, operationalized as at least a $30\\%$ reduction in average pain intensity on a $0$ to $10$ numeric rating scale without an increase in daily opioid dose. Let $p_{c}$ denote the probability of response in the placebo arm and $p_{t}$ denote the probability of response in the gabapentin arm. In this study, the observed response proportions were $p_{c} = 20\\%$ and $p_{t} = 40\\%$. Using fundamental definitions from clinical epidemiology regarding treatment effects based on differences in response probabilities, compute the number needed to treat for benefit for gabapentin with respect to this outcome. Provide your answer as a single real-valued number. No rounding is required.",
            "solution": "The number needed to treat (NNT) for benefit is based on the notion that treatment produces an incremental increase in the probability of achieving the desired outcome relative to control. The foundational quantities are the response probabilities in the control and treatment arms, denoted by $p_{c}$ and $p_{t}$, respectively.\n\nThe absolute treatment effect in a binary outcome framework is the absolute risk difference (also called the absolute benefit), which is defined as\n$$\n\\Delta = p_{t} - p_{c}.\n$$\nThe NNT for benefit is defined as the reciprocal of this absolute benefit:\n$$\n\\text{NNT} = \\frac{1}{\\Delta}.\n$$\nThis definition arises from the expectation that, under a Bernoulli outcome model and stable baseline risk, treating $1/\\Delta$ patients yields one additional responder compared to control on average.\n\nSubstitute the observed proportions. First, convert percentages to proportions:\n$$\np_{c} = 0.20, \\quad p_{t} = 0.40.\n$$\nCompute the absolute benefit:\n$$\n\\Delta = 0.40 - 0.20 = 0.20.\n$$\nCompute the NNT:\n$$\n\\text{NNT} = \\frac{1}{0.20} = 5.\n$$\nBecause $\\Delta$ is exactly $0.20$, the NNT is exactly $5$, and no rounding is required.",
            "answer": "$$\\boxed{5}$$"
        },
        {
            "introduction": "Effective psycho-oncologic care often involves managing psychotropic medications in patients with concurrent medical comorbidities. This advanced problem synthesizes multiple quantitative skills to address a realistic clinical scenario: adjusting a medication dose based on pharmacokinetic principles and designing a safety monitoring plan grounded in probability. This exercise demonstrates how to create a personalized and safe treatment regimen for a medically complex cancer patient. ",
            "id": "4747754",
            "problem": "A psycho-oncology patient is initiating treatment for cancer-related major depressive disorder with venlafaxine extended-release. Consider a $58$-year-old woman with metastatic breast cancer and Chronic Kidney Disease (CKD) stage $3\\text{a}$, with estimated glomerular filtration rate (eGFR) = $45\\,\\mathrm{mL\\,min^{-1}\\,(1.73\\,m^2)^{-1}}$. The planned starting dose of venlafaxine extended-release is $150\\,\\mathrm{mg\\,day^{-1}}$. You are asked to compute a renal dose adjustment to maintain the same steady-state exposure of the active moiety (venlafaxine plus O-desmethylvenlafaxine) as would be expected in normal kidney function and to specify quantitative monitoring for hypertension and serotonin toxicity during the first $14$ days.\n\nUse the following fundamental bases:\n\n- At steady state under linear pharmacokinetics, the average concentration is proportional to dose divided by total clearance: $\\bar{C}_{\\text{ss}} \\propto \\frac{D}{CL_{\\text{total}}}$.\n- Total clearance is the sum of organ clearances: $CL_{\\text{total}} = CL_{\\text{hepatic}} + CL_{\\text{renal}}$.\n- Renal clearance scales approximately linearly with glomerular filtration rate: $CL_{\\text{renal}} \\propto \\text{eGFR}$.\n- For the active moiety of venlafaxine, assume the fraction of total clearance attributable to the kidney under normal function is $f_{r} = 0.50$.\n- Take normal eGFR as $120\\,\\mathrm{mL\\,min^{-1}\\,(1.73\\,m^2)^{-1}}$.\n\nMonitoring specifications:\n\n- Hypertension monitoring: You aim to detect a true increase of $\\Delta = 10\\,\\mathrm{mmHg}$ in systolic blood pressure (SBP) within the first $14$ days with probability at least $0.95$ using repeated SBP measurements. Assume each measurement error is independent and normally distributed with standard deviation $\\sigma = 8\\,\\mathrm{mmHg}$, and define “detection” as observing any reading at least $\\Delta$ above the baseline SBP measured immediately before initiation. Schedule the SBP measurements at equal intervals across the $14$-day window. Compute the minimal equal-interval spacing in days that achieves the detection probability target.\n- Serotonin toxicity monitoring: The patient is co-prescribed serotonergic agents commonly used in oncology care. Assume that any serotonin toxicity episode in the initiation window, if it occurs, produces at least $L = 1.0\\,\\mathrm{day}$ of detectable symptoms (by structured symptom check using the Hunter Serotonin Toxicity Criteria). For a periodic symptom check every $d$ days, the probability of detecting a uniformly phased episode of duration $L$ is $p=1$ if $d \\leq L$, and otherwise $p = \\frac{L}{d}$. Choose the largest $d$ (in days) such that the detection probability is at least $0.90$.\n\nTasks:\n\n1. Compute the adjusted total daily dose $D_{\\text{adj}}$ (in $\\mathrm{mg\\,day^{-1}}$) that maintains the same steady-state active-moiety exposure as in normal kidney function under the assumptions above.\n2. Compute the minimal equal-interval spacing $d_{\\text{BP}}$ (in days) for SBP measurements over $14$ days to achieve the detection probability requirement.\n3. Compute the largest monitoring interval $d_{5\\text{HT}}$ (in days) for serotonin toxicity symptom checks that yields detection probability at least $0.90$.\n\nExpress the final dose in $\\mathrm{mg\\,day^{-1}}$ and monitoring intervals in days. Round all numerical results to four significant figures. Provide the final answer as a single row matrix containing, in order, $D_{\\text{adj}}$, $d_{\\text{BP}}$, and $d_{5\\text{HT}}$.",
            "solution": "The problem requires the computation of three quantities: a renal dose adjustment for venlafaxine, a monitoring interval for blood pressure, and a monitoring interval for serotonin toxicity. The solution is presented in three parts, corresponding to each task.\n\n### 1. Adjusted Venlafaxine Dose ($D_{\\text{adj}}$)\n\nThe primary goal is to adjust the dose $D$ to maintain the same average steady-state concentration ($\\bar{C}_{\\text{ss}}$) of the active moiety in a patient with renal impairment as would be achieved with a standard dose in a person with normal renal function. This is expressed as:\n$$\n\\bar{C}_{\\text{ss,patient}} = \\bar{C}_{\\text{ss,normal}}\n$$\nThe problem states that at steady state, $\\bar{C}_{\\text{ss}}$ is proportional to the dose divided by the total clearance ($CL_{\\text{total}}$): $\\bar{C}_{\\text{ss}} \\propto \\frac{D}{CL_{\\text{total}}}$. To maintain the same $\\bar{C}_{\\text{ss}}$, the following relationship must hold:\n$$\n\\frac{D_{\\text{adj}}}{CL_{\\text{total,patient}}} = \\frac{D_{\\text{normal}}}{CL_{\\text{total,normal}}}\n$$\nFrom this, we derive the formula for the adjusted dose:\n$$\nD_{\\text{adj}} = D_{\\text{normal}} \\times \\frac{CL_{\\text{total,patient}}}{CL_{\\text{total,normal}}}\n$$\nThe term $\\frac{CL_{\\text{total,patient}}}{CL_{\\text{total,normal}}}$ is the dose adjustment factor.\n\nTotal clearance is the sum of hepatic and renal clearances: $CL_{\\text{total}} = CL_{\\text{hepatic}} + CL_{\\text{renal}}$. We assume that hepatic clearance is unaffected by chronic kidney disease.\n\nFor an individual with normal kidney function, the total clearance is $CL_{\\text{total,normal}}$. The fraction of total clearance attributable to the kidney is given as $f_{r} = 0.50$. Therefore:\n$$\nCL_{\\text{renal,normal}} = f_{r} \\times CL_{\\text{total,normal}}\n$$\n$$\nCL_{\\text{hepatic}} = (1 - f_{r}) \\times CL_{\\text{total,normal}}\n$$\nFor the patient with renal impairment, renal clearance ($CL_{\\text{renal}}$) is assumed to scale linearly with the estimated glomerular filtration rate ($\\text{eGFR}$). The patient's renal clearance can be expressed as:\n$$\nCL_{\\text{renal,patient}} = CL_{\\text{renal,normal}} \\times \\frac{\\text{eGFR}_{\\text{patient}}}{\\text{eGFR}_{\\text{normal}}} = (f_{r} \\times CL_{\\text{total,normal}}) \\times \\frac{\\text{eGFR}_{\\text{patient}}}{\\text{eGFR}_{\\text{normal}}}\n$$\nThe patient's total clearance is the sum of their hepatic and reduced renal clearance:\n$$\nCL_{\\text{total,patient}} = CL_{\\text{hepatic}} + CL_{\\text{renal,patient}}\n$$\nSubstituting the expressions for $CL_{\\text{hepatic}}$ and $CL_{\\text{renal,patient}}$:\n$$\nCL_{\\text{total,patient}} = ((1 - f_{r}) \\times CL_{\\text{total,normal}}) + \\left((f_{r} \\times CL_{\\text{total,normal}}) \\times \\frac{\\text{eGFR}_{\\text{patient}}}{\\text{eGFR}_{\\text{normal}}}\\right)\n$$\nFactoring out $CL_{\\text{total,normal}}$, we find the ratio of the clearances:\n$$\n\\frac{CL_{\\text{total,patient}}}{CL_{\\text{total,normal}}} = (1 - f_{r}) + f_{r} \\times \\frac{\\text{eGFR}_{\\text{patient}}}{\\text{eGFR}_{\\text{normal}}}\n$$\nWe are given the following values:\n- Normal dose, $D_{\\text{normal}} = 150\\,\\mathrm{mg\\,day^{-1}}$\n- Fraction of renal clearance, $f_{r} = 0.50$\n- Patient's eGFR, $\\text{eGFR}_{\\text{patient}} = 45\\,\\mathrm{mL\\,min^{-1}\\,(1.73\\,m^2)^{-1}}$\n- Normal eGFR, $\\text{eGFR}_{\\text{normal}} = 120\\,\\mathrm{mL\\,min^{-1}\\,(1.73\\,m^2)^{-1}}$\n\nSubstituting these values into the dose adjustment factor expression:\n$$\n\\frac{CL_{\\text{total,patient}}}{CL_{\\text{total,normal}}} = (1 - 0.50) + 0.50 \\times \\frac{45}{120} = 0.50 + 0.50 \\times 0.375 = 0.50 + 0.1875 = 0.6875\n$$\nNow, we can compute the adjusted dose:\n$$\nD_{\\text{adj}} = 150\\,\\mathrm{mg\\,day^{-1}} \\times 0.6875 = 103.125\\,\\mathrm{mg\\,day^{-1}}\n$$\n\n### 2. Blood Pressure Monitoring Interval ($d_{\\text{BP}}$)\n\nThe objective is to find an equal-interval spacing, $d_{\\text{BP}}$, for blood pressure measurements over a $14$-day period to ensure detection of a true systolic blood pressure (SBP) increase of $\\Delta = 10\\,\\mathrm{mmHg}$ with a probability of at least $0.95$. A single measurement $M$ is a normal random variable with mean equal to the true SBP ($S_0 + \\Delta$, where $S_0$ is baseline) and standard deviation $\\sigma = 8\\,\\mathrm{mmHg}$. So, $M \\sim N(S_0 + \\Delta, \\sigma^2)$.\n\nDetection is defined as observing any reading $M \\ge S_0 + \\Delta$. The probability of detection in a single measurement, $p_1$, is:\n$$\np_1 = P(M \\ge S_0 + \\Delta)\n$$\nTo calculate this, we can standardize the variable $M$:\n$$\np_1 = P\\left(\\frac{M - (S_0 + \\Delta)}{\\sigma} \\ge \\frac{(S_0 + \\Delta) - (S_0 + \\Delta)}{\\sigma}\\right) = P(Z \\ge 0)\n$$\nwhere $Z$ is a standard normal random variable. This probability is $p_1 = 0.5$.\n\nIf $n$ independent measurements are taken, the probability of *not* detecting an increase in any of them is $(1 - p_1)^n = (0.5)^n$. The probability of at least one detection is therefore:\n$$\nP(\\text{detection}) = 1 - (0.5)^n\n$$\nWe require this probability to be at least $0.95$:\n$$\n1 - (0.5)^n \\ge 0.95 \\implies 0.05 \\ge (0.5)^n\n$$\nTaking the natural logarithm of both sides:\n$$\n\\ln(0.05) \\ge n \\ln(0.5) \\implies -\\ln(20) \\ge -n \\ln(2) \\implies n \\ln(2) \\ge \\ln(20)\n$$\n$$\nn \\ge \\frac{\\ln(20)}{\\ln(2)} \\approx \\frac{2.99573}{0.69315} \\approx 4.3219\n$$\nSince the number of measurements $n$ must be an integer, the minimum number of measurements required is $n_{\\min} = 5$.\n\nThe problem asks for the \"minimal equal-interval spacing\". This is ill-posed, as any spacing $d_{\\text{BP}} \\le 14/5 = 2.8$ days would result in $n = \\lfloor 14/d_{\\text{BP}} \\rfloor \\ge 5$ measurements, satisfying the detection criterion. The set of valid spacings, $(0, 2.8]$, has no minimum. A physically sensible and clinically relevant question is to find the *maximal* allowable spacing, which corresponds to the least frequent monitoring that meets the objective. We proceed by calculating this maximal spacing.\n\nAssuming the $n$ measurements are spaced such that they span the entire $T=14$-day window (e.g., measurements at $d, 2d, \\dots, nd$ with $nd=T$), the spacing is $d_{\\text{BP}} = T/n$. To find the maximal spacing, we use the minimal number of measurements, $n_{\\min}=5$:\n$$\nd_{\\text{BP,max}} = \\frac{14\\,\\text{days}}{5} = 2.8\\,\\text{days}\n$$\nWe provide this value as the answer, with the clarification that it represents the maximal, not minimal, valid spacing.\n\n### 3. Serotonin Toxicity Monitoring Interval ($d_{5\\text{HT}}$)\n\nThe goal is to find the largest monitoring interval, $d$, in days for a periodic symptom check that ensures a detection probability of at least $0.90$. The duration of a detectable symptom episode is at least $L = 1.0\\,\\mathrm{day}$.\n\nThe probability of detection, $p$, is given as a function of the interval $d$:\n$$\np(d) = \\begin{cases} 1 & \\text{if } d \\le L \\\\ L/d & \\text{if } d > L \\end{cases}\n$$\nWe need to find the largest $d$ such that $p(d) \\ge 0.90$. We analyze two cases:\n\nCase 1: $d \\le L$.\nIn this case, $d \\le 1.0\\,\\mathrm{day}$. The detection probability is $p(d) = 1$. Since $1 \\ge 0.90$, any interval $d$ in the range $(0, 1.0]$ is valid.\n\nCase 2: $d > L$.\nIn this case, $d > 1.0\\,\\mathrm{day}$. The detection probability is $p(d) = L/d = 1.0/d$. The condition is:\n$$\n\\frac{1.0}{d} \\ge 0.90\n$$\nSolving for $d$:\n$$\nd \\le \\frac{1.0}{0.90} = \\frac{10}{9}\n$$\nThus, for the case $d > 1.0$, the valid intervals are in the range $(1.0, 10/9]$.\n\nCombining both cases, the set of all valid monitoring intervals $d$ is $(0, 1.0] \\cup (1.0, 10/9]$, which simplifies to $(0, 10/9]$. The problem asks for the largest such interval, $d_{5\\text{HT}}$. The maximum value in this set is:\n$$\nd_{5\\text{HT}} = \\frac{10}{9}\\,\\text{days} \\approx 1.1111... \\,\\text{days}\n$$\n\n### Summary of Results\n\nThe three computed values are:\n1.  $D_{\\text{adj}} = 103.125\\,\\mathrm{mg\\,day^{-1}}$\n2.  $d_{\\text{BP}} = 2.8\\,\\text{days}$\n3.  $d_{5\\text{HT}} = 10/9\\,\\text{days}$\n\nRounding to four significant figures as requested:\n- $D_{\\text{adj}} \\approx 103.1\\,\\mathrm{mg\\,day^{-1}}$\n- $d_{\\text{BP}} = 2.800\\,\\text{days}$\n- $d_{5\\text{HT}} \\approx 1.111\\,\\text{days}$\n\nThese are presented as a single row matrix.",
            "answer": "$$\n\\boxed{\\begin{pmatrix} 103.1 & 2.800 & 1.111 \\end{pmatrix}}\n$$"
        }
    ]
}